Pictet Asset Management Holding SA Purchases 909 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Pictet Asset Management Holding SA increased its position in Inari Medical, Inc. (NASDAQ:NARI) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,935 shares of the company’s stock after buying an additional 909 shares during the period. Pictet Asset Management Holding SA’s holdings in Inari Medical were worth $405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Inari Medical during the 4th quarter worth approximately $14,447,000. Jennison Associates LLC increased its position in Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after purchasing an additional 186,617 shares during the last quarter. Evoke Wealth LLC raised its stake in Inari Medical by 207.5% during the fourth quarter. Evoke Wealth LLC now owns 192,926 shares of the company’s stock valued at $9,849,000 after purchasing an additional 130,186 shares in the last quarter. American Century Companies Inc. lifted its position in Inari Medical by 9.1% during the fourth quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after purchasing an additional 89,108 shares during the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Inari Medical in the 4th quarter worth $3,969,000. 90.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on NARI shares. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial boosted their target price on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. BTIG Research restated a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. Finally, Piper Sandler boosted their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Inari Medical currently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Price Performance

Inari Medical stock opened at $79.97 on Thursday. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The firm has a 50-day moving average of $79.95 and a two-hundred day moving average of $63.77. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.99.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.